lapatinib has been researched along with Pituitary Neoplasms in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Du, G; Lv, T; Ren, S; Sun, L; Wang, J; Yu, H | 1 |
| Bonert, VS; Cooper, O; Fleseriu, M; Lo, J; Melmed, S; Pressman, BD; Rudnick, J; Salvatori, R; Yuen, KCJ | 1 |
| Ben-Shlomo, A; Cooper, O | 1 |
| Bannykh, S; Ben-Shlomo, A; Bonert, V; Carmichael, J; Cook-Wiens, G; Cooper, O; Lim, S; Mamelak, A | 1 |
| Araki, T; Cooper, O; Fukuoka, H; Kano, M; Liu, X; Melmed, S; Tone, M; Tone, Y | 1 |
| Kim, EH; Kim, H; Lee, S; Park, Y; Suh, CO | 1 |
1 review(s) available for lapatinib and Pituitary Neoplasms
| Article | Year |
|---|---|
Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside.
Topics: Animals; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Lapatinib; Mice; Mice, Transgenic; Pituitary Neoplasms; Prolactinoma; Protein Kinase Inhibitors; Quinazolines; Translational Research, Biomedical | 2017 |
2 trial(s) available for lapatinib and Pituitary Neoplasms
| Article | Year |
|---|---|
EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Male; Middle Aged; Pituitary Neoplasms; Prognosis; Prolactinoma; Prospective Studies; Receptor, ErbB-2; Young Adult | 2021 |
Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lapatinib; Male; Middle Aged; Pilot Projects; Pituitary Neoplasms; Prolactinoma; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
3 other study(ies) available for lapatinib and Pituitary Neoplasms
| Article | Year |
|---|---|
Bexarotene combined with lapatinib for the treatment of Cushing's disease: evidence based on drug repositioning and experimental confirmation.
Topics: Adrenocorticotropic Hormone; Animals; Bexarotene; Drug Combinations; Drug Repositioning; Humans; Lapatinib; Mice; Nuclear Receptor Subfamily 4, Group A, Member 1; Pituitary ACTH Hypersecretion; Pituitary Neoplasms; Protein Interaction Maps; Retinoid X Receptor alpha | 2020 |
ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice.
Topics: Animals; Antineoplastic Agents; Enhancer Elements, Genetic; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Transgenic; Pituitary Neoplasms; Prolactinoma; Promoter Regions, Genetic; Quinazolines | 2015 |
Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Humans; Hypopituitarism; Lapatinib; Pituitary Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2016 |